Yearly Archives: 2016

/2016

Emotra’s application is given the “Seal of Excellence”

On November 28, Emotra announced that the Company’s Horizon 2020 application to the European Commission has been rejected. We have now had the opportunity to review the EC’s statement and we see that our application passed their threshold by a wide margin and that it was given a “Seal of Excellence”.   161130-emotra-nyhetsbrev-emotra-seal-of-excellence_en

By | November 30th, 2016|INVESTORS|Comments Off on Emotra’s application is given the “Seal of Excellence”

Future report dates for Emotra

Emotra’s Board of Directors has decided the following dates for release of financial reports and the annual shareholder meeting   161128-emotra-nyhetsbrev-dates-for-financial-reports-en

By | November 28th, 2016|INVESTORS|Comments Off on Future report dates for Emotra

European Commission Horizon 2020 – application rejected

The European Commission has rejected Emotra’s application for approximately 3 MEUR, which we intended to use for three purposes: First of all to finance EUDOR-Y, a clinical multi-centre study on young people, secondly to develop EDOR® Interconnect, and thirdly to further develop our hardware and software solutions. Emotra has not yet had the opportunity to [...]

By | November 28th, 2016|INVESTORS|Comments Off on European Commission Horizon 2020 – application rejected

Emotra – Lars-Håkan Thorell held presentation in Chicago

Last week in Chicago, Lars-Håkan Thorell, the inventor of EDOR® and the Company’s Head of research, held a presentation that gathered a great deal of attention. He presented the result of his research and how it led to the development of EDOR®. 161031-emotra-news-letter-thorell-presented-in-chicago

By | November 2nd, 2016|INVESTORS|Comments Off on Emotra – Lars-Håkan Thorell held presentation in Chicago

Emotra – Lars-Håkan Thorell praised by ECNP

This past week Lars-Håkan Thorell, the inventor of EDOR® and Emotra’s Head of research, has received a great deal of attention for his many years of research into identifying patients who are at risk of committing suicide. Thorell has been voted in as a member of the European College of Neuropsychopharmacology, ECNP. On Tuesday, September [...]

By | September 27th, 2016|INVESTORS|Comments Off on Emotra – Lars-Håkan Thorell praised by ECNP

A short update – Successful meetings for Emotra in Oviedo

During the past few days, on September 8–11, Emotra participated in the 16th European Symposium on Suicide and Suicidal Behaviour, ESSSB, in Oviedo, Spain. New, exciting studies on EDOR® were presented by research groups from Oviedo and Novara.   160913-emotra-newsletter-successful-convention-in-oviedo

By | September 13th, 2016|INVESTORS|Comments Off on A short update – Successful meetings for Emotra in Oviedo

A short update – Emotra is off to Oviedo for some meetings

During the next few days, on September 8–11, Emotra will be participating in the 16th European Symposium on Suicide and Suicidal Behaviour, ESSSB, in Oviedo, Spain. EDOR® will be presented in different contexts during the conference and a special workshop about the method will also be held. In addition to this, Emotra and Professor Marco [...]

By | September 8th, 2016|INVESTORS|Comments Off on A short update – Emotra is off to Oviedo for some meetings

Emotra has commissioned Laika to write an article about the Company.

The article was published on the business news site Privataaffärer.se. We have translated the article and inserted it below. Direct link to the article: http://www.investerarbrevet.se/pages/1947 New ventures in the fight against suicide 160902-emotra-newsletter-article-in-laika-with-article

By | September 8th, 2016|INVESTORS|Comments Off on Emotra has commissioned Laika to write an article about the Company.

Emotra AB (publ) Interim report Jan-June 2016

Styrelsen och verkställande direktören för Emotra AB (publ) avger härmed delårsrapport för första halvåret 2016. Sammanfattning perioden januari – juni 2016 · Nettoomsättningen uppgick till 273 kSEK (0) · Rörelseresultatet uppgick till -3 188 kSEK (-2 574) · Resultat per aktie efter utspädning -0,33 SEK (-0,56) · Likvida medel uppgick vid perioden utgång till 7 535 kSEK (2 040) · Fas 1 av kliniska multicenterstudien avklarad - 1573 patienter inkluderade i studien · Baselinematerialet visar god överensstämmelse med tidigare observationer · Rapport från Emotras ”EU:s Horizon 2020- förundersökningsstudie” inlämnad · EDOR® registrerat varumärke inom hela EU Sammanfattning perioden april – juni 2016 · Nettoomsättningen uppgick till 0 kSEK (0) · Rörelseresultatet uppgick till -1 760 kSEK (-1 322) · Resultat per aktie efter utspädning -0,18 SEK (-0,25)

By | August 24th, 2016|INVESTORS|Comments Off on Emotra AB (publ) Interim report Jan-June 2016